<DOC>
	<DOC>NCT00417690</DOC>
	<brief_summary>The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 4 grams three times daily for 2 weeks followed by 4 grams twice daily for 2 weeks, will resolve an acute flare of ileocecal Crohn's disease.</brief_summary>
	<brief_title>High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<criteria>Age 1865 Crohn's disease involving predominantly the ileum and/or cecum. The diagnosis must have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3 modalities) with at least one confirmatory test having been performed no more than 36 months before entry. The diagnosis must have been confirmed by at least one gastroenterologist. Harvey Bradshaw Index of at least 7 The onset of the acute flare should have been abrupt, declaring itself over 72 hours, and should have started no more than 4 weeks before study entry. Symptoms relating to the flare should not have diminished or started to improve prior to entry. Written informed consent Concomitant corticosteroids, including budesonide Corticosteroids within the previous 2 months Cyclosporine, mycophenolate mofetil or experimental drugs during the last three months Maintenance infliximab, or infliximab or other biologics in the preceding 3 months Change in dose during previous 4 weeks in 5aminosalicylate, probiotic and/or antibiotic, or in chronic azathioprine, 6mercaptopurine, or methotrexate If currently using azathioprine, 6mercaptopurine or methotrexate, these must have been used steadily for at least 4 months Current experimental drugs or experimental drugs within the last 3 months If the severity of the flare has started to decrease spontaneously Coexisting diagnosis of primary sclerosing cholangitis, Infectious diarrhea, Signs of intestinal obstruction or perforation or abscess, New fistulization as part of the acute flare or increased activity in chronic fistula(e) as part of the acute flare, Increased activity of preexisting anal or rectal Crohn's disease as part of the flare Allergy or sensitivity to salicylates Pregnancy or breastfeeding Failure of a woman of childbearing age to agree to use adequate contraception for the 4 week period of the trial, if sexually active Severe renal or hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Acute Flare</keyword>
	<keyword>Mild to moderate Crohn's Disease</keyword>
	<keyword>Ileocecal distribution</keyword>
</DOC>